Bedeutung der 68Ga – DOTATATE PET/CT in der Diagnostik von transossären Meningeomen

Meningeome sind mit circa 38% bei Frauen und 20% bei Männern die am häufigsten diagnostizierten Hirntumoren und machen etwa 30% aller Hirntumoren aus. Aktuell stellt die kontrastverstärkte MRT die Modalität der Wahl bei Diagnose von Meningeomen dar. Da Meningeome in der Regel eine erhöhte SSTR-2-Expression aufweisen und die Anreicherung von 68Ga-DOTATATE im Gewebe mit der SSTR-2-Expression korreliert, bietet die SSTR-PET/CT eine Bildgebungsalternative insbesondere für Meningeome in komplexen anatomischen Regionen. Die Hypothese dieser Arbeit war, dass die 68Ga-DOTATATE PET/CT eine verbesserte Detektion von intraossärem Wachstum in der Meningeomdiagnostik aufweist als die KM-MRT. Im Zeitraum zwischen August 2010 und Januar 2016 wurden insgesamt 327 Patienten retrospektiv eingeschlossen. Diese Kohorte wurde aufgrund fehlender MRT-Bildgebung innerhalb von 30 Tagen, nicht-diagnostischer Bildqualität sowie aufgrund fehlender pathologischer Informationen auf 82 Patienten reduziert. In der endgültigen Studienpopulation zeigten 15 Patienten (18,3%) extraossäre Meningeome und 67 Patienten (81,7%) transossäre Meningeome. Transossäre Meningeome hatten einen signifikant höheren SUVmax (14,2 vs. 7,6; p = 0,011) und SUVmean (4,3 vs. 2,7; p = 0,001) als extraossäre Meningeome. Transossäre Meningeome wiesen sowohl in der 68Ga-DOTATATE PET/CT (12,8 vs. 3,3 ml; p < 0,001) als auch in der KM-MRT (10,6 vs. 2,5 ml; p = 0,001) signifikant größere Volumina auf. Die Sensitivität der 68Ga-DOTATATE PET/CT für die Detektion einer ossären Beteiligung war signifikant höher als die der KM-MRT (98,5% vs. 53,7%; p < 0,001) ohne Einbussen in der Spezifität (p = 0,200). Volumetrische Messungen der Meningeome zeigten keine signifikanten intermodalen Unterschiede für extraossäre Meningeome (p = 0,132) und den extraossären Anteil transossärer Meningeome (p = 0,636) basierend auf dem Wilcoxon-Rangtest. Im Gegensatz dazu wurde der intraossäre Anteil der transossären Meningeome durch die 68Ga-DOTATATE PET/CT signifikant größer (6,8 vs. 3,3 ml; p < 0,001) volumetriert als in der KM-MRT. Zusammenfassend konnte eine signifikant höhere Sensitivität von 68Ga-DOTATATE PET/CT in Bezug auf die Darstellung der ossären Manifestation im Vergleich zur KM-MRT zeigen, die vor allem aus einem höheren Tumor-Hintergrund-Kontrast resultiert. Zudem konnte anhand einer Tumor-3D-Visualisierung mit Hilfe von Traceraufnahmewerten eine räumliche Darstellung des Tumors erfolgen. Die PET/CT hat demnach das Potential einer exakteren Abgrenzung der intraossären Komponente transossärer Meningeome

Swiss Pilot Low-Dose CT Lung Cancer Screening Study: First Baseline Screening Results

This pilot study conducted in Switzerland aims to assess the implementation, execution, and performance of low-dose CT lung cancer screening (LDCT-LCS). With lung cancer being the leading cause of cancer-related deaths in Switzerland, the study seeks to explore the potential impact of screening on reducing mortality rates. However, initiating a lung cancer screening program poses challenges and depends on country-specific factors. This prospective study, initiated in October 2018, enrolled participants meeting the National Lung Cancer Study criteria or a lung cancer risk above 1.5% according to the PLCOm2012 lung cancer risk-model. LDCT scans were assessed using Lung-RADS. Enrollment and follow-up are ongoing. To date, we included 112 participants, with a median age of 62 years (IQR 57–67); 42% were female. The median number of packs smoked each year was 45 (IQR 38–57), and 24% had stopped smoking before enrollment. The mean PLCOm2012 was 3.7% (±2.5%). We diagnosed lung cancer in 3.6% of participants (95%, CI:1.0–12.1%), with various stages, all treated with curative intent. The recall rate for intermediate results (Lung-RADS 3,4a) was 15%. LDCT-LCS in Switzerland, using modified inclusion criteria, is feasible. Further analysis will inform the potential implementation of a comprehensive lung cancer screening program in Switzerland

Comparability of Pulmonary Nodule Size Measurements among Different Scanners and Protocols: Should Diameter Be Favorized over Volume?

BACKGROUND: To assess the impact of the lung cancer screening protocol recommended by the European Society of Thoracic Imaging (ESTI) on nodule diameter, volume, and density throughout different computed tomography (CT) scanners. METHODS: An anthropomorphic chest phantom containing fourteen different-sized (range 3-12 mm) and CT-attenuated (100 HU, -630 HU and -800 HU, termed as solid, GG1 and GG2) pulmonary nodules was imaged on five CT scanners with institute-specific standard protocols (P$_{S}$) and the lung cancer screening protocol recommended by ESTI (ESTI protocol, P$_{E}$). Images were reconstructed with filtered back projection (FBP) and iterative reconstruction (REC). Image noise, nodule density and size (diameter/volume) were measured. Absolute percentage errors (APEs) of measurements were calculated. RESULTS: Using P$_{E}$, dosage variance between different scanners tended to decrease compared to P$_{S}$, and the mean differences were statistically insignificant (p = 0.48). P$_{S}$ and P$_{E(REC)}$ showed significantly less image noise than P$_{E(FBP)}$ (p < 0.001). The smallest size measurement errors were noted with volumetric measurements in P$_{E(REC)}$ and highest with diametric measurements in P$_{E(FBP)}$. Volume performed better than diameter measurements in solid and GG1 nodules (p < 0.001). However, in GG2 nodules, this could not be observed (p = 0.20). Regarding nodule density, REC values were more consistent throughout different scanners and protocols. CONCLUSION: Considering radiation dose, image noise, nodule size, and density measurements, we fully endorse the ESTI screening protocol including the use of REC. For size measurements, volume should be preferred over diameter

Impact of photon-counting-detector-CT derived virtual-monoenergetic-images and iodine-maps on the diagnosis of pleural empyema

PURPOSE The purpose of this study was to evaluate the impact of virtual monoenergetic image (VMI) energies and iodine maps on the diagnosis of pleural-empyema with photon-counting-detector computed-tomography (PCD-CT). MATERIALS AND METHODS In this IRB-approved retrospective study, consecutive patients with non-infectious pleural effusion or histopathology-proven empyema were included. PCD-CT examinations were performed on a dual-source PCD-CT in the multi-energy (QuantumPlus) mode at 120 kV with weight-adjusted intravenous contrast-agent. VMIs from 40-70 keV obtained in 10 keV intervals and an iodine map was reconstructed for each scan. CT-attenuation was measured in the aorta, the pleura and the peripleural fat (between autochthonous dorsal muscles and dorsal ribs). Contrast-to-noise (CNR) and signal-to-noise (SNR) ratios were calculated. Two blinded radiologists evaluated if empyema was present (yes/no), and rated diagnostic confidence (1 to 4; not confident to fully confident, respectively) with and without using the iodine map. Sensitivity, specificity and diagnostic confidence were estimated. Interobserver agreement was estimated using an unweighted Cohen kappa test. A one-way ANOVA was used to compare variables. Differences in sensitivity and specificity between the different levels of energy were searched using McNemar test. To compare AUC values DeLong test was performed. McNemar test was performed to compare values for sensitivity and specificity. RESULTS Sixty patients (median age, 60 years; 26 women) were included. A strong negative correlation was found between image noise and VMI energies (r = -0.98; P = 0.001) and CNR increased with lower VMI energies (r = -0.98; P = 0.002). Diagnostic accuracy (96%; 95% CI: 82-100) as well as diagnostic confidence (3.4 ± 0.75 [SD]) were highest at 40 keV. Diagnostic accuracy and confidence at higher VMI energies improved with the addition of iodine maps (P ≤0.001). Overall, no difference in CT attenuation of peripleural fat between patients with empyema and those with pleural effusion was found (P = 0.07). CONCLUSION Low VMI energies lead to a higher diagnostic accuracy and diagnostic confidence in the diagnosis of pleural empyema. Iodine maps help in diagnosing empyema only at high VMI energies

Impact of radiation dose on the detection of interstitial lung changes and image quality in low-dose chest CT - Assessment in multiple dose levels from a single patient scan

PURPOSE To assess image quality and detectability of interstitial lung changes using multiple radiation doses from the same chest CT scan of patients with suspected interstitial lung disease (ILD). METHOD Retrospective study of consecutive adult patients with suspected ILD receiving unenhanced chest CT as single-energy dual-source acquisition at 100 kVp (Dual-split mode). 67% and 33% of the overall tube current time product were assigned to tube A and B, respectively. 100%-dose was 2.34 ± 0.97 mGy. Five different radiation doses (100%, 67%, 45%, 39%, 33%) were reconstructed from this single acquisition using linear-blending technique. Two blinded radiologists assessed reticulations, ground-glass opacities (GGO) and honeycombing as well as subjective image noise. Percentage agreement (PA) as compared to 100%-dose were calculated. Non-parametric statistical tests were used. RESULTS A total of 228 patients were included (61.2 ± 14.6 years,146 female). PA was highest for honeycombing (>96%) and independent of dose reduction (P > 0.8). PA for reticulations and GGO decreased when reducing the radiation dose from 100% to 67% for both readers (reticulations: 83.3% and 93.9%; GGO: 87.7% and 79.8% for reader 1 and 2, respectively). Additional dose reduction did not significantly change PA for both readers (all P > 0.05). Subjective image noise increased with decreasing radiation dose (Spearman Rho of ρ = 0.34 and ρ = 0.53 for reader 1 and 2, respectively, P < 0.001). CONCLUSIONS Radiation dose reduction had a stronger impact on subtle interstitial lung changes. Detectability decreased with initial dose reduction indicating that a minimum dose is needed to maintain diagnostic accuracy in chest CT for suspected ILD

The Swiss Approach - feasibility of a national low-dose CT lung cancer screening program.

BACKGROUND Lung cancer is the leading cause of cancer-related deaths in Switzerland. Despite this, there is no lung cancer screening program in the country. In the United States, low-dose computed tomography (LDCT) lung cancer screening is partially established and endorsed by guidelines. Moreover, evidence is growing that screening reduces lung cancer-related mortality and this was recently shown in a large European randomized controlled trial. Implementation of a lung cancer screening program, however, is challenging and depends on many country-specific factors. The goal of this article is to outline a potential Swiss lung cancer screening program. FRAMEWORK An exhaustive literature review on international screening models as well as interviews and site visits with international experts were initiated. Furthermore, workshops and interviews with national experts and stakeholders were conducted to share experiences and to establish the basis for a national Swiss lung cancer screening program. SCREENING APPROACH General practitioners, pulmonologists and the media should be part of the recruitment process. Decentralisation of the screening might lead to a higher adherence rate. To reduce stigmatisation, the screening should be integrated in a "lung health check". Standardisation and a common quality level are mandatory. The PLCOm2012 risk calculation model with a threshold of 1.5% risk for developing cancer in the next six years should be used in addition to established inclusion criteria. Biennial screening is preferred. LUNG RADS and NELSON+ are applied as classification models for lung nodules. CONCLUSION Based on data from recent studies, literature research, a health technology assessment, the information gained from this project and a pilot study the Swiss Interest Group for lung cancer screening (CH-LSIG) recommends the timely introduction of a systematic lung cancer screening program in Switzerland. The final decision is for the Swiss Cancer Screening Committee to make

The Swiss Approach - feasibility of a national low-dose CT lung cancer screening program

BACKGROUND Lung cancer is the leading cause of cancer-related deaths in Switzerland. Despite this, there is no lung cancer screening program in the country. In the United States, low-dose computed tomography (LDCT) lung cancer screening is partially established and endorsed by guidelines. Moreover, evidence is growing that screening reduces lung cancer-related mortality and this was recently shown in a large European randomized controlled trial. Implementation of a lung cancer screening program, however, is challenging and depends on many country-specific factors. The goal of this article is to outline a potential Swiss lung cancer screening program. FRAMEWORK An exhaustive literature review on international screening models as well as interviews and site visits with international experts were initiated. Furthermore, workshops and interviews with national experts and stakeholders were conducted to share experiences and to establish the basis for a national Swiss lung cancer screening program. SCREENING APPROACH General practitioners, pulmonologists and the media should be part of the recruitment process. Decentralisation of the screening might lead to a higher adherence rate. To reduce stigmatisation, the screening should be integrated in a "lung health check". Standardisation and a common quality level are mandatory. The PLCOm2012 risk calculation model with a threshold of 1.5% risk for developing cancer in the next six years should be used in addition to established inclusion criteria. Biennial screening is preferred. LUNG RADS and NELSON+ are applied as classification models for lung nodules. CONCLUSION Based on data from recent studies, literature research, a health technology assessment, the information gained from this project and a pilot study the Swiss Interest Group for lung cancer screening (CH-LSIG) recommends the timely introduction of a systematic lung cancer screening program in Switzerland. The final decision is for the Swiss Cancer Screening Committee to make

Liver Iodine Quantification With Photon-Counting Detector CT: Accuracy in an Abdominal Phantom and Feasibility in Patients

RATIONALE AND OBJECTIVES To compare the accuracy of iodine quantification in liver parenchyma and lesions between dual-source photon-counting detector CT (PCD-CT) and dual-source energy-integrating detector CT (EID-CT) in a phantom and to demonstrate the feasibility of iodine quantification with PCD-CT in liver parenchyma and lesions in patients. MATERIALS AND METHODS An anthropomorphic abdominal phantom with a liver insert containing parenchyma and lesions was imaged on a clinical PCD-CT at 120kV and in the dual-energy mode on an EID-CT with kV-combinations of 80/Sn150kV, 90/Sn150kV, and 100/Sn150kV. Three patient sizes were imaged at three different radiation doses (CTDI$_{vol}$: 5, 10, 15mGy). Thirty patients with liver cysts, hemangiomas or metastases imaged with PCD-CT were retrospectively included. Iodine maps were reconstructed and iodine concentrations were measured in liver parenchyma and lesions. For the phantom, iodine error was quantified as the absolute difference to the vendor's specifications as reference. RESULTS Overall iodine error was 0.33 ± 0.29, 0.34 ± 0.32, 0.39 ± 0.37, 0.35 ± 0.39 mgI/mL for 80/Sn150kV, 90/Sn150kV, 100/Sn150kV of EID-CT, and PCD-CT, respectively, without significant differences between PCD-CT and EID-CT (p > 0.05). Radiation dose did not significantly influence error of PCD-CT (p > 0.05) nor EID-CT (p > 0.05). For both scanners, smaller patient sizes were associated with lower errors (p 0.05). In patients, iodine quantification was feasible in liver parenchyma, cysts, hemangiomas, and metastases. CONCLUSION Iodine quantification with PCD-CT is accurate in simulated liver parenchyma and lesions irrespective of radiation dose, iodine concentration, and base attenuation and is feasible in common liver lesions in patients

Swiss Pilot Low-Dose CT Lung Cancer Screening Study: First Baseline Screening Results

This pilot study conducted in Switzerland aims to assess the implementation, execution, and performance of low-dose CT lung cancer screening (LDCT-LCS). With lung cancer being the leading cause of cancer-related deaths in Switzerland, the study seeks to explore the potential impact of screening on reducing mortality rates. However, initiating a lung cancer screening program poses challenges and depends on country-specific factors. This prospective study, initiated in October 2018, enrolled participants meeting the National Lung Cancer Study criteria or a lung cancer risk above 1.5% according to the PLCOm2012 lung cancer risk-model. LDCT scans were assessed using Lung-RADS. Enrollment and follow-up are ongoing. To date, we included 112 participants, with a median age of 62 years (IQR 57–67); 42% were female. The median number of packs smoked each year was 45 (IQR 38–57), and 24% had stopped smoking before enrollment. The mean PLCOm2012 was 3.7% (±2.5%). We diagnosed lung cancer in 3.6% of participants (95%, CI:1.0–12.1%), with various stages, all treated with curative intent. The recall rate for intermediate results (Lung-RADS 3,4a) was 15%. LDCT-LCS in Switzerland, using modified inclusion criteria, is feasible. Further analysis will inform the potential implementation of a comprehensive lung cancer screening program in Switzerland

Sarcopenia, Precardial Adipose Tissue and High Tumor Volume as Outcome Predictors in Surgically Treated Pleural Mesothelioma

Background: We evaluated the prognostic value of Sarcopenia, low precardial adipose-tissue (PAT), and high tumor-volume in the outcome of surgically-treated pleural mesothelioma (PM). Methods: From 2005 to 2020, consecutive surgically-treated PM-patients having a pre-operative computed tomography (CT) scan were retrospectively included. Sarcopenia was assessed by CT-based parameters measured at the level of the fifth thoracic vertebra (TH5) by excluding fatty-infiltration based on CT-attenuation. The findings were stratified for gender, and a threshold of the 33rd percentile was set to define sarcopenia. Additionally, tumor volume as well as PAT were measured. The findings were correlated with progression-free survival and long-term mortality. Results: Two-hundred-seventy-eight PM-patients (252 male; 70.2 ± 9 years) were included. The mean progression-free survival was 18.6 ± 12.2 months, and the mean survival time was 23.3 ± 24 months. Progression was associated with chronic obstructive pulmonary disease (COPD) (p = p = 0.001), and type of surgery (p = 0.026). Three-year mortality was associated with higher patient age (p = 0.005), presence of COPD (p p = 0.015), and higher tumor-volume (p p = 0.002). While there was a negative correlation of progression-free survival and mortality with tumor volume (r = 0.281, p = 0.001 and r = −0.240, p p = 0.040). Conclusions: Sarcopenia as well as tumor volume are associated with long-term mortality in surgically treated PM-patients. Further, while there was a negative correlation of progression-free survival and mortality with tumor volume, a correlation with PAT could only be shown for epithelioid PM